Clinical Trials
3 trialsNCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT04330664 2025-04-04
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT04975256 2024-12-16
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
Phase 1 Terminated